Pfizer withdraws leukaemia drug Mylotarg from US market on safety and efficacy concerns
This article was originally published in Scrip
Executive Summary
Pfizer is pulling a ten-year old product – the monoclonal antibody Mylotarg (gemtuzumab ozogamicin) – from the US market effective mid-October after a postmarketing study showed a higher death rate and no benefit to patients with acute myeloid leukaemia (AML), the US FDA said in a statement.
You may also be interested in...
Pfizer's Mylotarg Finally Gets CHMP Nod But No New Indication For Sutent
The EMA is finally set to approve Pfizer's targeted anticancer Mylotarg for use in acute myeloid leukemia. The company also received opinions for Bosulif and Sutent.
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.